$NVS (Novartis AG)

$NVS {{ '2016-09-19T10:48:23+0000' | timeago}} • Announcement

Pharma company $NVS reported positive results of Phase III EXPAND study. It showed that oral once-daily BAF312 (siponimod) significantly reduced risk of disability progression versus placebo in people with secondary progressive multiple sclerosis. This is a form of multiple sclerosis with continuous worsening of neurological function over time.

$GILD {{ '2018-01-18T17:34:32+0000' | timeago}} • Announcement

Kite, a $GILD company, has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the combination of Yescarta and Pfizer's utomilumab, in patients with refractory large B-cell lymphoma. A multi-center Phase 1/2 study sponsored by Kite is expected to begin in 2018.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$ACOR {{ '2018-01-08T12:56:05+0000' | timeago}} • Announcement

Bio-pharmaceuticals company $ACOR has reported net sales of $542MM for fiscal 2017. For fiscal 2018, the company expects net sales to be in the range of $330MM to $350MM. R&D and SG&A operating expenses, on an adjusted basis, is forecasted in the $270-$290MM range.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$GILD {{ '2017-12-15T12:38:30+0000' | timeago}} • Announcement

$GILD announced that Executive Chairman John Martin will transition from his current role of Executive Chairman to Chairman of the Board of Directors effective March 9, 2018.

$GILD {{ '2017-12-12T14:09:39+0000' | timeago}} • Announcement

Kite, a $GILD company, announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 CAR T cell therapy, which is investigational for treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL). 71% of ALL patients who received a single infusion of KTE-C19 achieved complete tumor remission.

$ZTS {{ '2017-12-12T13:32:16+0000' | timeago}} • Announcement

$ZTS BoD declared 1Q18 dividend of $0.126 per share of the company’s common stock, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$GILD {{ '2017-12-11T13:19:50+0000' | timeago}} • Announcement

Kite, a $GILD company reported that 58% of  patients with advanced blood cancer, who underwent a one-time treatment of its Yescarta therapy, showed complete remission after a median of 15 months. The company added that 42% of the patients continued to respond to therapy, after the duration of this period

$GILD {{ '2017-12-08T12:53:28+0000' | timeago}} • Announcement

$GILD and Kite agreed to acquire Cell Design Labs, Inc. $GILD will acquire all outstanding shares of Cell Design Labs, which includes approx. 12.2% of shares held by Kite, for up to approx. $567MM. The agreement includes an initial upfront payment of about $175MM and milestone payments of up to $322MM. The acquisition is expected to close shortly.

$ACOR {{ '2017-12-07T14:24:01+0000' | timeago}} • Announcement

$ACOR announced the resubmission of its New Drug Application (NDA) for INBRIJA to the US FDA. INBRIJA is an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. FDA is expected to inform $ACOR within 74 days if the submission has been deemed complete and permits a full review.

$GILD {{ '2017-12-04T15:30:42+0000' | timeago}} • Announcement

$GILD launched the Gilead COMPASS Initiative, a 10-year, $100MM commitment to support organizations working to address the HIV/AIDS epidemic in Southern US. $GILD will partner with the Emory University Rollins School of Public Health, the University of Houston Graduate College of Social Work and the Southern AIDS Coalition for this initiative.

$ACOR {{ '2017-11-20T13:09:44+0000' | timeago}} • Announcement

$ACOR stops developing its Parkinson’s disease drug tozadenant. This decision comes a week after the drugmaker reported five deaths in key studies testing the treatment. The company would stop enrolling patients in two long-term safety trials after it found seven cases of sepsis in mid- and late-stage trials.

$ACOR {{ '2017-11-17T15:46:22+0000' | timeago}} • Announcement

$ACOR announced a $40MM royalty monetization with HealthCare Royalty Partners (HCR) and a $13MM royalty monetization with H. Lundbeck A/S. H. Lundbeck and $ACOR have amended the license agreement for Selincro to eliminate future royalty and milestone obligations on sales of Selincro outside of the United States.

$ACOR {{ '2017-11-15T12:23:57+0000' | timeago}} • Announcement

$ACOR said it has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

$ACOR {{ '2017-11-15T12:23:21+0000' | timeago}} • Announcement

$ACOR lifted frequency of blood cell count monitoring for participants to weekly in Phase 3 program of tozadenant for Parkinson's disease. $ACOR took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death. Agranulocytosis is absence of white blood cells, which fight infection.

$ZTS {{ '2017-11-07T19:49:47+0000' | timeago}} • Infographic

$ZTS Zoetis Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$VRX {{ '2017-11-07T19:06:31+0000' | timeago}} • Announcement

$VRX said it will sell Sprout, the subsidiary that produces Addyi-the female libido pill, to a former shareholder of Sprout in exchange for a 6% royalty on global sales of Addyi. The sale is expected to close before the end of 2017. Addyi is the only approved and commercialized product of Sprout.

$VRX {{ '2017-11-07T14:58:15+0000' | timeago}} • Announcement

$VRX said as of Nov. 7, 2017 it reduced its total debt by approx.  $6Bil since the end of 1Q16.  As of Nov. 7, 2017, approx. 80% of the company's debt is fixed rate debt.

$VRX {{ '2017-11-07T14:54:18+0000' | timeago}} • Announcement

$VRX has maintained its guidance for FY17 Adj. EBITDA to $3.60-3.75Bil. The company updated its FY17 revenue to the range of $8.65-8.80Bil from $8.70-8.90Bil.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
ARQL (ArQule Inc.)
Thursday, November 9 2017 - 2:00pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
NVS (Novartis AG)
Tuesday, October 24 2017 - 12:00pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm

AlphaGraphics you may like